ACE and focal segmental glomerulosclerosis: The mainstay of therapy for FSGS has traditionally included angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs), glucocorticoids, and calcineurin inhibitors.[7] However, novel therapies have opened doors for various treatment options such that knowledge of key risk predictors would be instrumental in stratifying patients for timely interventions.